AC Immune (ACIU) Interest & Investment Income (2014 - 2026)

AC Immune (ACIU) has reported Interest & Investment Income for 12 consecutive years, with $291157.1 the latest figure, recorded in Q1 2026.

• In Q1 2026, Interest & Investment Income fell 61.9% year-over-year to $291157.1; the TTM figure through Mar 2026 stood at $1.7 million (down 52.62% YoY), while the FY2025 annual figure was $2.2 million, down 38.34% from the prior year.
• Interest & Investment Income retreated to $291157.1 in Q1 2026 per ACIU's latest filing, from $441662.9 in the prior quarter.
• Across five years, Interest & Investment Income topped out at $1.1 million in Q3 2024 and bottomed at -$435044.8 in Q2 2022.
• Historically, Interest & Investment Income has averaged $389061.7 across 5 years, with a median of $322663.5 in 2023.
• Annual changes were most pronounced in 2022 — Interest & Investment Income sank 263.25% — and 2023, when it surged 2732.86%.
• AC Immune's Interest & Investment Income stood at $60205.3 in 2022, then soared by 216.46% to $190522.9 in 2023, then surged by 432.65% to $1.0 million in 2024, then sank by 56.48% to $441662.9 in 2025, then sank by 34.08% to $291157.1 in 2026.
• Business Quant data shows ACIU's Interest & Investment Income at $291157.1 in Q1 2026, $441662.9 in Q4 2025, and $457540.1 in Q3 2025.